Lorillard
Fields
- Author
- Lavoie, E.J.
- Type
- LETT, LETTER
- CHAR, CHART/GRAPH
- Document File
- 01112767/01113018/American Health Fndn Dr D Hoffman.
- Alias
- 01112884/01112888
- Area
- SCHULTZ/FILES BY FRANCES RICHMOND'S DESK
- Site
- G60
- Characteristic
- MARG, MARGINALIA
- Copied
- Spears, A.W.
- Minnemeyer, H.J.
- Schultz, F.J.
- Minnemeyer, H.J.
- Request
- R1-004
- R1-077
- Named Organization
- Hewlettpackard
- Date Loaded
- 05 Jun 1998
- Author (Organization)
- Ahf, American Health Foundation
- Named Person
- Fow, E.
- Hoffmann, D.
- Tulley, L.
- Hoffmann, D.
- Recipient
- Bell, J.H.
- Litigation
- Stmn/Produced
- Brand
- Golden Lights
- Pall Mall
- UCSF Legacy ID
- qje81e00
Document Images
AMERiCARI HEALTH FOUisIDATiON
NAYLOR DANA INSTITUTE FOR DISEASE PREVENTION
Dana Road, Valhalla, New York 10595 Telephone: 914-592-2600
American Hlsallh Foundation
320 East 43rd Stteet
New York, New York 10017
Telephone:,212-953-1900
OFFICERS AND
BOARD OFT9USTEES
David J. Mahoney, Chairman Dr. Jimmy H. Bell
Chairman and Chief Executive Otficer Lorl l l ard
Norton Simon, Inc. i.~
William J. Levhta,Past'Chairman IKes$arcii Center
Founder-Chairman
levitt dSona, Inc. t'. 420 English Street
Ernat L. Wynder, M.D., President p.Q.BOx 21688
John D. Twiname, Managing Ditecton Green abOIO y N. C. 2 7 4 2 0
Eric M. Javits, Secretary ;~
Senior Partner
Javits & Javlts
TRUSTEES: .
JohnJ. Burns, Ph.D.
Vice President for,Research
HoNmann-La RoctieInc.
Thomas L. Chrystle
Chairman
Merrill Lynch White Weld
Capital Markets Group
Theodore Coaper, M.D.
Dean
Cornell University Medical'College
Mrs. Charles A. Dana
D. Ronald Daniel
Managing Director,
McKinsey & Companyj,lnc.
Ralph Landau, Sc.D:
Chairman & Chief Executive Officer
Haicon International,Jnc.
Hildegarde E.,Mahoney
Bruce S. Nevins
President
Perrier, Great Waters of France, Inc.
Joseph Robbie
Managing Partner
Miami Dolphins, Ltd.
Hon. Donald'H. Rumsfeld
President d Chief~Executive Officer
G.D. Searle & Gompany
John W. Simmons
Presitlenf8 Chief Executive Officer
Morton-Norwich Products, Inc.
Mrs. Jennifer Jones Simon
Thomas A. Watson
ADM. E. R. Zumwalt, Jr., USN (Ret.)
President 8 Chief~Execut)vs Officer
American MedicallBuildings, Inc.
David L. Davies
Executive Vice President
John H. Weiaburger, Ph.D.
Vice President for Research
Naylor Dana Institute
Charles B. Arnold, M.Di. M,P.H.
Vice President for Research
Health Maintenance Institute
Dear Dr. Bell:
I have enclosed the data from the samples
which you have forwarded to Dr. Hoffmann. We
have found that our current methods of collect-
ing the distillate from tobacco provides us with
very consistent mutagenicity results. Because
of the potential for "hot spots" in qur initial
distilling apparatus, we employed a modified
unit using a Hewlett-Packard gas-chromatograph
as illustrated in figure 1. U.sing this unit it
was found that under our standard conditions
(flow rate = 50 ml per minute using He carrier
gas) almost complete.transfer of distille , mater-
ial at a specific temperature occurred afte 1.0
hour. Our initial studies using this apparatus
involved heating at temperaturesof 200°, 250°,
and 300°'. No mutagenic activity was observed
in S. typhimurium TA 98 at 200° in either the
whole distillate of its basic subfraction. At
250°, where most of the largest amount of di-
stillate is collected, only marginal mutagenic
activity was observed. Only at 300° have we
found mutagenic activity of at least 4 x con-
trol levels (DMSO) for the whole distillate.
2

NAYLOR DANA INSTITUTE
for DISEASE PREVENTION
2
It is our current practice, therefore, to di-
still tobacco at 2500 for 1.0 hour, then to
replace the traps and continue the distilla-
tion at 300°C for an additional hour.
The mutagenicity assays on your fractions A,
B, and C are outlined in Table 1. There is
little doubt that your chemical procedures
are effective in concentrating the mutage-
nic activity. Table 2 outlines the results
of our stepwise temperature distillation
procedure using 200°, 250°, and 300°C.
Tncluded are the results of mutagenicity
assays of the neutral, basic, and acidic
fractions of these spe-cific distillates. All
solutions for bioassay are prepared using
Aldrich "Gold Label" dimethylsulphoxide.
If we can be of any furthe r assistance in
this study, please do not hesitate to call
on us. Miss Lorraine Tulley or Miss Eliza-
beth-Ann Fow are available to assist you in
establishingidentical mutagenicity assay pro-
cedures, if you feel this is required.
Sincerely,
Edmond J.LaVoie, Ph.D.
Head
Section of Metabolic Biochemistry
Div. of Environmental Carcinogenesis
encl.
EJL/bs
cc. Dr. F.J. Schultz

r
Table 1.
HIS+RE'VEFtANTS
PLATE
SAMPLE
DOSE
.PLATE
(ug)
PLATE PLATE
I II
f.
X ~jr
~
1000
7).Y- 80
75 y8- y
0
500 Go 7S - 65 lsS 4Z s
s:,-
,. A
250
YG.~- 55
38
100 c
Z 49 35 3~'sL 3~
C?/.
50 ~
33
18
25 17 2 5
1000 yy 3~ 9 8 81 rz
500 !1 Z- 113 ill
B 250 1yZ. 148 136
100 11 `l 100 128
50 ~3 84 102 13/ sv 33 3Y
25 58 53
1000 lbp,s- 114 87 /~8- 1/9 ?6
500 /7ys-153 206 ;tr? t7$'./Y7
C 250 ~ Sz 131 173 /'31
/*Q~~ 100 8y>91 88 a' ? 6r 'S2
5 0 S (- 50 62 33 ' 30
25 3!y 31 32
Strain . TA . 98; Spont.: 18 Control DMSO: 19

Table
AVERAGE (HIS+ B2EVERTANTS/PLATE)''
TEMPERATURE
(° C) PLATE
( l,tg ) TRAP
I TRAP
I I
NEUTRALS 1
BASES 1
ACIDS 1
1000 50 50 31 77 43
500 46 48 36 69 36
200
250 48 44 40 .36 30
100 50 32' 33 39 26
100U 34 43 48' 33 25
2'50 500 34 46 40 25. 28
250 40 48 42 23 32
100 50 51 45 1$ 37
1000 60 46 52 90 46
500 67 45 48 108 42
300
250 60 41 49 92 38
100 42 39 45 100 35
Strain TA.98; Spont:20 Control DMSO: 20
1Fractions of combined materials of Trap I and II.

;
01112888
